Pharmacokinetics and Target Attainment of Fluoroquinolones in Older Adults: A Systematic Review
Pharmacokinetics and Target Attainment of Fluoroquinolones in Older Adults: A Systematic Review

Pharmacokinetics and Target Attainment of Fluoroquinolones in Older Adults: A Systematic Review

Clin Pharmacokinet. 2025 Dec 5. doi: 10.1007/s40262-025-01603-3. Online ahead of print.

ABSTRACT

BACKGROUND AND OBJECTIVE: Fluoroquinolones are among the most frequently prescribed antibiotics in older adults. Age-related pharmacokinetic (PK) changes can affect treatment efficacy and increase the risk of adverse drug reactions. This systematic review provides a comprehensive overview of the current knowledge on the PK and PK/pharmacodynamic (PD) target attainment of fluoroquinolones in older adults to inform strategies for personalised fluoroquinolone therapy.

METHODS: A comprehensive search of the Medline, Embase, Web of Science and Scopus databases was conducted. Relevant articles published before 1 December 2024 were included when they contained data on the PK of fluoroquinolones in older adults (median age ≥ 65 years). Extracted information included PK parameters, significant covariates influencing PK parameters, PK/PD target attainment rates and dosing recommendations. The ClinPK Statement checklist was used for quality grading.

RESULTS: Fifty-five articles were included in this review, encompassing a total of 1542 non-critically ill older adults and 585 younger controls. Eight articles (14.5%) identified covariates with a significant effect on PK parameters. Most of these covariates (66.7%) were indicators of renal function. PK/PD target attainment was assessed in 30.9%, and dosing recommendations were provided in 61.8% of all included PK studies. Studies had an average quality score of 65.9% (standard deviation, SD ± 12.3%).

CONCLUSIONS: High-quality PK studies on fluoroquinolones in older adults remain sparse. While a substantial amount of the included articles provided dosing recommendations, only a minority did so on the basis of PK/PD target attainment data. The limited application of advanced PK/PD modeling and simulation approaches hampers the development of evidence-based, individualised fluoroquinolone dosing strategies in older adults.

TRIAL REGISTRATION: Prospectively registered in PROSPERO.

TRIAL REGISTRATION NUMBER: CRD42023480126. Registration date: 17/11/2023.

PMID:41348398 | DOI:10.1007/s40262-025-01603-3